The American Academy of Neurology (AAN) annual meeting, scheduled for April 25-May 1, 2020, was cancelled due to the COVID-19 pandemic. The following summarizes some of the new research that would have been presented at AAN 2020.
Neurology
Siponimod – new data in SPMS
April 23, 2020Click here to take the SPMS survey
Siponimod, the selective sphingosine-1-phosphate (S1P) receptor modulator (S1P1,5), produces a sustained reduction in worsening disability for up to five years in patients with secondary-progressive MS (SPMS), according to data submitted to the American Academy of Neurology annual meeting (Kappos et al. AAN 2020; abstract S40.003).
FDA approves ozanimod in MS
April 16, 2020The U.S. Food and Drug Administration has approved ozanimod (Zeposia) for the treatment of relapsing forms of MS, including clinically isolated syndrome (CIS), RRMS and active SPMS. The drug was developed by Receptos, then acquired by Celgene before Celgene was acquired in turn by Bristol-Myers Squibb. Ozanimod was submitted for review by Health Canada in December 2019. Read More
MS 2020 – the view from a decade ago
March 18, 2020“It’s difficult to make predictions – especially about the future.” – Yogi Berra
A decade ago, Dr. Aaron Miller, Mount Sinai, New York, took a game swing at the crystal ball and wrote the article, “Multiple sclerosis: where will we be in 2020?” (Miller A. Mt Sinai J Med 2011;78:268-279). Read More
Evaluating acute migraine therapies: ICER
March 11, 2020The Institute for Clinical and Economic Review (ICER), a drug pricing watchdog in the U.S., has ruled that novel oral migraine therapies have similar effectiveness but are not superior to triptans (5-HT 1B/1D agonists). Read More